The standard approach to a patient with a solitary brain metastasis from melanoma has been surgical removal followed by radiation. This approach allows for pathologic diagnosis and molecular characterization or, for a large symptomatic lesion, the best opportunity for decompression and symptomatic relief. Radiation is currently used for a majority of such patients, in the form of whole-brain radiation and/or stereotactic radiosurgery, with each technique having its own inherent risks and benefits. In the article that accompanies this commentary, Chukwueke et al 1 present a nice update of newer systemic options for patients with melanoma with brain metastases. The newer options discussed include melanoma-specific driver mutation inhibitors, such as the BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors, such as those targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death ligand-1.
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Systemic Options for Melanoma Brain Metastases
In support of potential efficacy of BRAF inhibitors in this setting, the authors quote a pilot study of 24 patients 1 
Implications for Radiation Oncology
The emergence of these newer agents has also raised cautious optimism for the radiation oncologist, because BRAF inhibitors may increase radiation sensitivity and/or toxicity.
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The increased radiation sensitivity with the use of BRAF inhibitors may also allow for radiation dose modification to help turn a radioresistant melanoma into a potentially radiosensitive one, leading to durable postradiation responses in combination with BRAF inhibitors. There is also excitement about the potential of enhanced postradiotherapy "abscopal" effects 10 in combination with newer immune checkpoint inhibitors.
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As newer agents make their way through the trials, we suspect that the future management of melanoma brain metastases will become even more dependent on multidisciplinary approaches. Patients will have many more options to choose from. These newer agents also open up several research opportunities to re-evaluate older thought processes, such as modification to the melanoma-specific graded prognostic assessment when taking into account BRAF status and/or immune responses to newer immune checkpoint inhibitors. Further trials are necessary to determine how to best optimize radiotherapy in combination with the newer agents. 
